Keros Therapeutics, Inc. (NASDAQ: KROS) has announced the final results of its cash tender offer to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of US$17.75 per share, for an aggregate purchase price of up to US$194.4 million. The Tender Offer expired on November 18, 2025, concluding the Company’s previously announced US$375 million capital return program. On November 20, 2025, the Company announced that it has accepted for purchase a total of 10,950,165 shares of its common stock, for an aggregate purchase price of US$194.4 million.
Latham & Watkins LLP represented the dealer manager in the Tender Offer with a Capital Markets team led by partners Greg Rodgers and Nathan Ajiashvili, with associate Brice Stewart, and with assistance from Alondra Tlatelpa. Advice was also provided on tax matters by partner Eric Cho, with assistance from Daniel Mousseri.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
